Keywords: ligand/lilly, ppar, drug, faces, delay, ligand, pharmaceuticals

Ligand/Lilly's PPAR drug faces delay

Article | 19 July 2004

Ligand Pharmaceuticals has revealed that Phase III studies for itsinvestigational diabetes treatment naveglitazar (LY818) will be delayed by around 18-24 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Lilly

Go to company listing

Related Drugs

Alpha

Prolastin

Nystatin

Go to drug listing